Kentaro Sudo

Kentaro Sudo

Auto-generated profile, based on publicly available information

Kentaro Sudo

Division of Gastroenterology, Chiba Cancer Centre, Chiba, Japan.

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KSKentaro Sudo
Kentaro Sudo
TYTaketo Yamaguchi
Taketo Yamaguchi
TITakeshi Ishihara
Takeshi Ishihara
KNKazuyoshi Nakamura
Kazuyoshi Nakamura
THTaro Hara
Taro Hara
OYOsamu Yokosuka
Osamu Yokosuka

30 March 2010 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KSKentaro Sudo
Kentaro Sudo
TYTaketo Yamaguchi
Taketo Yamaguchi
KNKazuyoshi Nakamura
Kazuyoshi Nakamura
TDTadamichi Denda
Tadamichi Denda
THTaro Hara
Taro Hara
OYOsamu Yokosuka
Osamu Yokosuka

10 December 2013 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KSKentaro Sudo
Kentaro Sudo
TITakeshi Ishihara
Takeshi Ishihara
NHNobuto Hirata
Nobuto Hirata
FOFumiaki Ozawa
Fumiaki Ozawa
TOTadashi Ohshima
Tadashi Ohshima
TYTaketo Yamaguchi
Taketo Yamaguchi

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KSKentaro Sudo
Kentaro Sudo
KNKazuyoshi Nakamura
Kazuyoshi Nakamura
TYTaketo Yamaguchi
Taketo Yamaguchi
S-1 is an oral 5-fluorouracil (5-FU) prodrug, which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase, the key enzyme of 5-FU catabolism. Recently, two important studies on the clinical use of S-1 for pancreatic cancer have been reported from Japan. In the first study (GEST study), S-1 demonstrated non-inferiority to gemcitabine (GEM) in overall survival (OS) for metastatic or locally advanced pancreatic cancer, but combination chemotherapy with GEM and S-1 did not show superiority to GEM in OS. In the second study (JASPAC-01 study), S-1 showed superiority to adjuvant chemotherapy with GEM in OS in patients with resected pancreatic cancer. In addition to GEM, S-1 is now regarded as the key drug in the management of pancreatic cancer in Japan. To date, many studies have investigated the effectiveness of S-1 in various settings, such as first-line chemotherapy for metastatic or locally advanced pancreatic cancer, second-line chemotherapy after GEM failure, and chemoradiotherapy for locally advanced disease. In this review, we focus on recent clinical trials of S-1-based chemotherapy for advanced pancreatic cancer.

4 February 2016 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
PDF file
EKEmiri Kita
Emiri Kita
TYTaketo Yamaguchi
Taketo Yamaguchi
KSKentaro Sudo
Kentaro Sudo

7 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ATAkiko Tsujimoto
Akiko Tsujimoto
KSKentaro Sudo
Kentaro Sudo
KNKazuyoshi Nakamura
Kazuyoshi Nakamura
EKEmiri Kita
Emiri Kita
RHRyusuke Hara
Ryusuke Hara
TYTaketo Yamaguchi
Taketo Yamaguchi
Overall survival in a phase III study for metastatic pancreatic cancer has significantly improved with gemcitabine (GEM) plus nab-paclitaxel. However, to date, there is limited data on the efficacy and safety of its use for patients with locally advanced (LA) or borderline resectable pancreatic cancer (BRPC). Here, we investigated the efficacy and safety of first-line GEM plus nab-paclitaxel for LA or BRPC. We retrospectively analysed consecutive patients with pathologically confirmed, untreated LA or BRPC who started receiving first-line GEM plus nab-paclitaxel. A total of 30 patients (LA, n = 22; BRPC, n = 8) were analysed. Twelve patients (40%) without distant metastasis received additional chemoradiotherapy using S-1. Laparotomy was performed on 8 patients and 6 (20%; LA, n = 3; BR, n = 3) achieved R0 resection. Objective response rate was 44.8%. For all patients, median progression-free survival and overall survival were 14.8 and 29.9 months, respectively. Median overall survival for LA was 24.1 months with a 2-year survival rate of 50.8%. The most frequently observed grade 3 or 4 toxicities were neutropenia (73%) and biliary infection (13%). First-line GEM plus nab-paclitaxel was well-tolerated and feasible with an encouraging survival for LA or BRPC.